Trondl, R., Heffeter, P., Jakupec, M. A., Berger, W., & Keppler, B. K. (2012). NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BioMed Central.
Style de citation ChicagoTrondl, Robert, Petra Heffeter, Michael A. Jakupec, Walter Berger, et Bernhard K. Keppler. NKP-1339, a First-in-class Anticancer Drug Showing Mild Side Effects and Activity in Patients Suffering From Advanced Refractory Cancer. BioMed Central, 2012.
Style de citation MLATrondl, Robert, et al. NKP-1339, a First-in-class Anticancer Drug Showing Mild Side Effects and Activity in Patients Suffering From Advanced Refractory Cancer. BioMed Central, 2012.
Attention : ces citations peuvent ne pas être correctes à 100%.